Bafna Pharmaceuticals (NSE:BAFNAPH) Total Assets: ₹1,755 Mil (As of Mar. 2026)


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
60 GF Score
Price ₹214.63
GF Value ₹91.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Total Assets?

Bafna Pharmaceuticals NSE:BAFNAPH +5.00% 60 Total Assets is ₹1,755 Mil as of Mar. 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.79 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Bafna Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was ₹1,755 Mil.

During the past 12 months, Bafna Pharmaceuticals's average Total Assets Growth Rate was 14.80% per year. During the past 3 years, the average Total Assets Growth Rate was 12.20% per year. During the past 5 years, the average Total Assets Growth Rate was 16.00% per year. During the past 10 years, the average Total Assets Growth Rate was -0.60% per year.

During the past 13 years, Bafna Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 42.80%. The lowest was -29.30%. And the median was 12.20%.

Total Assets is connected with ROA %. Bafna Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was 6.26%. Total Assets is also linked to Revenue through Asset Turnover. Bafna Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 was 0.24.

Bafna Pharmaceuticals  (NSE:BAFNAPH) Total Assets Explanation

Total Assets is connected with ROA %.

Bafna Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=109.964/( (0+1755.324)/ 1 )
=109.964/1755.324
=6.26 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Bafna Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=422.393/( (0+1755.324)/ 1 )
=422.393/1755.324
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Bafna Pharmaceuticals Total Assets Related Terms

Bafna Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals Total Assets Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 901.45 1,295.83 1,476.82 1,530.79 1,755.32

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,530.79 0.00 1,606.83 0.00 1,755.32
NSE:BAFNAPH
60GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Bafna Pharmaceuticals's Total Assets for the fiscal year that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (A: Mar. 2026 )+Total Liabilities (A: Mar. 2026 )
=961.495+793.829
=1,755

Bafna Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=961.495+793.829
=1,755

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of ₹1,755 Mil mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Total Assets of ₹1,755 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' Total Assets too high?
Bafna Pharmaceuticals' current Total Assets is ₹1,755 Mil. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Total Assets compare to ZTS and UTHR?
Bafna Pharmaceuticals' Total Assets of ₹1,755 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current Total Assets is ₹1,755 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.79, compared to a current price of ₹214.63 — trading 133.8% above its estimated fair value. The current Total Assets is ₹1,755 Mil. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Total Assets is ₹1,755 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹214.63 is trading 133.8% above its estimated GF Value™ of ₹91.79. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Total Assets: ₹1,755 Mil
  • GF Value™: ₹91.79 vs. price of ₹214.63 (133.8% above fair value)
  • GF Score™: 60/100 with 8 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score

Get the complete analysis for NSE:BAFNAPH

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹214.63
Price
₹91.79
GF Value